Search research articles
Contact Us
Filters
Showing results (71-80 of 101) with videos related to
Page
of 11
Sort By:
British Journal of Haematology
|
November 19, 2013
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia
Aneel Paulus, Kasyapa Chitta, Sharoon Akhtar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 8, 2006
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study
Asher Chanan-Khan, Kena C Miller, Laurie Musial, et al.
British Journal of Haematology
|
May 11, 2011
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients
Taimur Sher, Sikander Ailawadhi, Kena C Miller, et al.
The Lancet. Haematology
|
December 5, 2016
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study
Richard R Furman, Herbert A Eradat, Christine G DiRienzo, et al.
Leukemia & Lymphoma
|
January 15, 2016
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial
Clemens M Wendtner, Michael Hallek, Graeme A M Fraser, et al.
The New England Journal of Medicine
|
August 25, 2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo, Asher Chanan-Khan, Katja Weisel, et al.
Blood
|
June 30, 2023
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
John F Seymour, John C Byrd, Paolo Ghia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Pieter Sonneveld, Asher Chanan-Khan, Katja Weisel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 10, 2012
Cancer- and chemotherapy-induced anemia
George M Rodgers, Pamela Sue Becker, Morey Blinder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 19, 2023
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Sikander Ailawadhi, Zi Chen, Bo Huang, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 101) with videos related to
Sort By:
Page
of 11
British Journal of Haematology
|
November 19, 2013
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia
Aneel Paulus, Kasyapa Chitta, Sharoon Akhtar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 8, 2006
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study
Asher Chanan-Khan, Kena C Miller, Laurie Musial, et al.
British Journal of Haematology
|
May 11, 2011
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients
Taimur Sher, Sikander Ailawadhi, Kena C Miller, et al.
The Lancet. Haematology
|
December 5, 2016
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study
Richard R Furman, Herbert A Eradat, Christine G DiRienzo, et al.
Leukemia & Lymphoma
|
January 15, 2016
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial
Clemens M Wendtner, Michael Hallek, Graeme A M Fraser, et al.
The New England Journal of Medicine
|
August 25, 2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo, Asher Chanan-Khan, Katja Weisel, et al.
Blood
|
June 30, 2023
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
John F Seymour, John C Byrd, Paolo Ghia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Pieter Sonneveld, Asher Chanan-Khan, Katja Weisel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 10, 2012
Cancer- and chemotherapy-induced anemia
George M Rodgers, Pamela Sue Becker, Morey Blinder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 19, 2023
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Sikander Ailawadhi, Zi Chen, Bo Huang, et al.
Page
of 11